Shares Outstanding for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported diluted shares outstanding is 136.28M. Diluted weighted-average shares outstanding is the share count used to compute per-share metrics like EPS. Buybacks lower it; new issuance, stock-based compensation, and convertible securities raise it. Multiply by the stock price for market capitalization.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingShares OutstandingSwitch metric
Latest period
136.28M
YoY change
+5.5%
5Y CAGR
+3.2%
Peak year (2025)
134.68M
Latest annual
134.68M
Shares Outstanding history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Shares Outstanding history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Shares Outstanding | YoY |
|---|---|---|---|---|
| 2025 | 134.68M | +5.5% | ||
| 2024 | 127.65M | +2.2% | ||
| 2023 | 124.91M | +2.6% | ||
| 2022 | 121.69M | +2.7% | ||
| 2021 | 118.45M | +3.0% | ||
| 2020 | 114.99M | +5.2% | ||
| 2019 | 109.26M | +8.6% | ||
| 2018 | 100.59M | +11.1% | ||
| 2017 | 90.55M | +5.8% | ||
| 2016 | 85.60M | +1.9% | ||
| 2015 | 83.99M | +13.1% | ||
| 2014 | 74.28M | +20.7% | ||
| 2013 | 61.55M | +22.4% | ||
| 2012 | 50.29M | +18.6% | ||
| 2011 | 42.41M | +0.9% | ||
| 2010 | 42.04M | +1.0% | ||
| 2009 | 41.63M | +1.4% | ||
| 2008 | 41.08M | +6.3% | ||
| 2007 | 38.66M | +21.2% | ||
| 2006 | 31.89M | +45.3% | ||
| 2005 | 21.95M | +84.7% | ||
| 2004 | 11.89M | +1160.9% | ||
| 2003 | 942,665 | +184.5% | ||
| 2002 | 331,341 | — |
Shares Outstanding values are taken from Alnylam Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual diluted shares outstanding for Alnylam Pharmaceuticals (ALNY) came in at 134.68M – grew 5.5% year-over-year.
Alnylam Pharmaceuticals diluted shares outstanding compound annual growth for the 2020–2025 (5 years) window is +3.2%, sustaining 23 straight years of year-over-year growth.
2025 marks the peak diluted shares outstanding at 134.68M, with the historical low of 331,341 recorded in 2002.
Among 8 Healthcare peers, Alnylam Pharmaceuticals (ALNY) ranks 9th; the peer median for diluted shares outstanding is 1.34B.
Alnylam Pharmaceuticals Shares Outstanding by Year
Alnylam Pharmaceuticals Shares Outstanding 2025: 134.68M
Alnylam Pharmaceuticals diluted shares outstanding in 2025 was 134.68M, grew 5.5% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Shares Outstanding 2024: 127.65M
Alnylam Pharmaceuticals diluted shares outstanding in 2024 was 127.65M, edged up 2.2% from 2023.
Alnylam Pharmaceuticals Shares Outstanding 2023: 124.91M
Alnylam Pharmaceuticals diluted shares outstanding in 2023 was 124.91M, edged up 2.6% from 2022.
Alnylam Pharmaceuticals Shares Outstanding 2022: 121.69M
Alnylam Pharmaceuticals diluted shares outstanding in 2022 was 121.69M, edged up 2.7% from 2021.
Alnylam Pharmaceuticals Shares Outstanding 2021: 118.45M
Alnylam Pharmaceuticals diluted shares outstanding in 2021 was 118.45M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Shares Outstanding
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest diluted shares outstanding.
| Company | Shares Outstanding | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | 4.45B | Healthcare |
| Merck & Co., Inc. (MRK) | 2.51B | Healthcare |
| Johnson & Johnson (JNJ) | 2.43B | Healthcare |
| AbbVie Inc. (ABBV) | 1.77B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | 910.00M | Healthcare |
| Eli Lilly and Company (LLY) | 898.00M | Healthcare |
| AstraZeneca PLC (AZN) | 781.00M | Healthcare |
| Amgen Inc. (AMGN) | 542.00M | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's diluted shares outstanding?
- Latest reported diluted shares outstanding for Alnylam Pharmaceuticals (ALNY) is 136.28M (period ending December 31, 2025).
How has Alnylam Pharmaceuticals diluted shares outstanding changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) diluted shares outstanding changed +5.5% year-over-year on the latest annual filing.
What is the long-term growth rate of Alnylam Pharmaceuticals diluted shares outstanding?
- Alnylam Pharmaceuticals (ALNY) diluted shares outstanding compound annual growth rate is +3.2% over the most recent 5 years available.
When did Alnylam Pharmaceuticals diluted shares outstanding hit its highest annual value?
- Alnylam Pharmaceuticals diluted shares outstanding reached its highest annual value of 134.68M in 2025.
What was Alnylam Pharmaceuticals diluted shares outstanding in 2024?
- Alnylam Pharmaceuticals (ALNY) diluted shares outstanding in 2024 was 127.65M.
What was Alnylam Pharmaceuticals diluted shares outstanding in 2025?
- Alnylam Pharmaceuticals (ALNY) diluted shares outstanding in 2025 was 134.68M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.